This page shows the latest Fycompa news and features for those working in and with pharma, biotech and healthcare.
Eisai did likewise for its epilepsy treatment Fycompa (perampanel).
The new unit will market the company's epilepsy drug Fycompa (perampanel), which it has been giving a rolling launch across the region. ... Fycompa indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised
New Melbourne base to support marketing of Halaven and Fycompa. Japan-based pharma firm Eisai has extended its global expansion with a new office in Melbourne, Australia. ... Fycompa is the first in a new class of treatment for partial onset seizures,
But company has better news on cancer drug Halaven. . Eisai's efforts to secure favourable pricing for its epilepsy drug Fycompa in Germany have hit the buffers once again. ... The German Federal Joint Committee (G-BA) has concluded once again that
Epilepsy is a relative new area of focus for Eisai, whose treatment options include Fycompa (perampanel), which was launched in Europe in 2012.
Eisai has issued a damning statement criticising Germany's healthcare watchdog IQWIG for not backing epilepsy drug Fycompa. ... IQWIG's recommendation will now be considered by the G-BA, which is expected to published a decision on Fycompa's use in
More from news
Approximately 10 fully matching, plus 9 partially matching documents found.
by adding a new solid dose global manufacturing line for its anti-epileptic medicine Fycompa. ... Fycompa was the first Eisai-developed epilepsy drug and it's “a drug we can really differentiate”, says Hendler.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...